


PHARMACEUTICAL 2022

Hoth Therapeutics Inc. Rank 445 of 475





PHARMACEUTICAL 2022

Hoth Therapeutics Inc. Rank 445 of 475

The relative strengths and weaknesses of Hoth Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hoth Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 206% points. The greatest weakness of Hoth Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 502% points.

The company's Economic Capital Ratio, given in the ranking table, is -781%, being 504% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	10,575
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	868
Liabilities, Non-Current	0
Other Assets	410
Other Compr. Net Income	33
Other Expenses	6,747
Other Liabilities	235
Other Net Income	-212
Property and Equipment	0
Research and Development	7,355
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	10,985
Liabilities	1,103
Expenses	14,101
Stockholders Equity	9,882
Net Income	-14,314
Comprehensive Net Income	-14,297
Economic Capital Ratio	-781%